PHONG PHU PHARMACEUTICAL JOINT STOCK COMPANY
No.: 11/2026/PP-TCK
(Re: Explanation of the Net Profit after income tax Discrepancy in the 2026 Audited Reviewed Interim Financial Statements)

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Ho Chi Minh City, Aug. 19th, 2026

<u>To:</u> - STATE SECURITIES COMMISSION
- HANOI STOCK EXCHANGE

Phong Phu Pharmaceutical Joint Stock Company hereby provides an explanation regarding the discrepancy in Net Profit after income tax in the 2026 Audited Reviewed Interim Financial Statements for the period from January 1, 2026 to June 30, 2026, as follows:

1. The Audited Reviewed Interim Financial Statements for the period from January 1, 2026 to June 30, 2026:
- Net Profit after income tax for 2026 Interim financial statements: VND 19,346,404,192
- Net Profit after income tax for 2025 Interim financial statements: VND 9,437,894,239
- Increase amount : VND 9,908,509,953
- Increase rate : 105%
2. The Audited Reviewed Interim Consolidated Financial Statements for the period from January 1, 2026 to June 30, 2026:
- Net Profit after income tax for 2026 Interim financial statements: VND 19,944,541,684
- Net Profit after income tax for 2025 Interim financial statements: VND 8,845,057,026
- Increase amount : VND 11,099,484,658
- Increase rate : 125.5 %

The primary reason for this increase in profit:

- The Audited Reviewed Interim Financial Statements:
  + Sales revenue increased by 6.2% compared to the same period last year
  + Financial income increased by 149% over to the same period last year driven by higher interest income from savings deposits and increased profits from the business operations of subsidiaries
  + % Cost of goods sold/revenues from sale decreased 2.5% compared to the same period last year, because the volume of goods warehoused during the period was higher than in the same period last year
  + Other income for the period increased higher, driven by compensation and support payments received for the repossession of factory facilities under a state-led site clearance project
- The Audited Reviewed Interim Consolidated Financial Statements:
  + Consolidated Sales revenue increased by 20.6% compared to the same period last year
  + % Cost of goods sold/revenues from sale decreased 4.8% compared to the same period last year.
  + Financial income increased by 76,3% over to the same period last year driven by higher interest income from savings.

As a result, the Net Profit after income tax in the 2026 Audited Reviewed Interim financial statements and Audited Reviewed Interim consolidated financial statements is higher than in 2025.

M.S.D.N:030142 CÔNG CỔ PH DƯỢC P PHONG P.TÂN TẠO - TP.H

Through this official letter, Phong Phu Pharmaceutical Joint Stock Company reports and explains the matter to the relevant authorities.

Sincerely,

PHONG PHU PHARMACEUTICAL JOINT STOCK COMPANY
GENERAL DIRECTOR

M.S.D.N:0301427564-C.T.C.P
CÔNG TY CỔ PHẦN DƯỢC PHẨM PHONG PHÚ
P.TÂN TẠO - TP.HỒ CHÍ MINH

TỔNG GIÁM ĐỐC

Thái Nhã Ngôn

Recipients:

- As stated above;
- Office archives.